NL
DE
14 March 2019
PD-MitoQUANT focuses on how mitochondria, the ‘powerhouses’ of the cell, contribute to cell death and neurodegeneration when they malfunction. The project involves 14 partners from 9 countries, including academic experts from the Royal College of Surgeons in Ireland, Institut du Cerveau et de la Moelle Epinière, German Center for Neurodegenerative Diseases, Neuroscience Institute of the National Research Council, University College London, Radboud University Medical Centre, the Centre National de la Recherche Scientifique, SMEs (GeneXplain GmbH, Mimetas, Pintail Limited), pharmaceutical companies (Teva Pharmaceutical Industries Ltd.; H. Lundbeck A/S; UCB S.A.), and a patient advocacy organization (Parkinson’s UK).
Innovative Medicines Initiative (IMI): link.
Werner Koopman, theme Mitochondrial diseases, received 400,000 euro as a member of the PD-MitoQUANT consortium. The latter is an EU-funded Innovative Medicines Initiative research project that will improve our understanding of Parkinson’s so that better treatments can be developed in the future.
PD-MitoQUANT focuses on how mitochondria, the ‘powerhouses’ of the cell, contribute to cell death and neurodegeneration when they malfunction. The project involves 14 partners from 9 countries, including academic experts from the Royal College of Surgeons in Ireland, Institut du Cerveau et de la Moelle Epinière, German Center for Neurodegenerative Diseases, Neuroscience Institute of the National Research Council, University College London, Radboud University Medical Centre, the Centre National de la Recherche Scientifique, SMEs (GeneXplain GmbH, Mimetas, Pintail Limited), pharmaceutical companies (Teva Pharmaceutical Industries Ltd.; H. Lundbeck A/S; UCB S.A.), and a patient advocacy organization (Parkinson’s UK).
Innovative Medicines Initiative (IMI): link.
Related news items
Hans Spelbrink is beneficiary of the MITGEST Doctoral Network which receives 2.6 million euros funding (PhD positions available)
27 September 2022EU has granted the new Doctoral Network “MITGEST” (Quality Control of the Mitochondrial Gene Expression System in Health and Disease), of which Radboudumc is one of the partners, with 2.6 million euros of funding under the Marie Sklodowska-Curie Actions.
read more
Towards a better understanding of Leigh Syndrome pathology and intervention published in Brain
8 December 2021 Melissa van de Wal and colleagues recently published a comprehensive review in the journal Brain on how Ndufs4 knockout mouse models have been used to unravel the pathomechanism of Leigh Syndrome. read more
New genetic defect links cell biology and protein glycosylation
10 November 2021 Peter Linders, Dirk Lefeber and Geert van den Bogaart together with international colleagues have recently reported on novel cell biological insights, by identifying a genetic disorder in syntaxin-5 which allowed to unravel a new mechanism regulating intracellular transportation. read more
Werner Koopman 25 years at Radboudumc celebrating online
8 July 2020 Werner Koopman completed his 25 years at Radboudumc. Biochemistry sent him a cake at home and celebrated this special moment during COVID-19 in a unique way. read more
Biodegradable nanoreactors demonstrate ROS shielding in human-complex-I-deficient fibroblasts
9 July 2018 Researchers of the Radboudumc and colleagues have successfully developed enzyme-loaded polymersomal nanoreactors capable of undergoing cellular integration in a controlled fashion and, subsequently, function as synthetic organelles. read more
